Compounds > cefcanel daloxate
Page last updated: 2024-12-08

cefcanel daloxate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cefcanel daloxate: pro-drug to improve oral absorption of KY-087; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID179697
SCHEMBL ID1230536
MeSH IDM0131973

Synonyms (17)

Synonym
cefcanel daloxate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (6r,7r)-7-[[(2r)-2-[(2s)-2-aminopropanoyl]oxy-2-phenylacetyl]amino]-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
cefcanel daloxato [inn-spanish]
unii-d9693uhf82
cefcanelum daloxatum [inn-latin]
97275-40-6
cefcanel daloxato
cefcanelum daloxatum
cefcanel daloxate [inn]
l-alanine, 2-((2-(((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-7-yl)amino)-2-oxo-1-phenylethyl ester, monohydrochloride, (6r-(6alpha,7beta(r*)))-
2,3-dihydroxy-2-butenyl (6r,7r)-7-((r)-mandelamido)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, cyclic 2,3-carbonate, ester with l-alanine
d9693uhf82 ,
cefcanel daloxate [who-dd]
cefcanel daloxate [mart.]
SCHEMBL1230536
Q27276258
AKOS040745658

Research Excerpts

Overview

Cefcanel daloxate hydrochloride is a new oral cephalosporin prodrug.

ExcerptReferenceRelevance
"Cefcanel daloxate hydrochloride is a new oral cephalosporin prodrug. "( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function.
Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994)		2.03
"Cefcanel daloxate is a new prodrug cephalosporin for oral use, with cefcanel as the antibacterially active principle. "( In vivo efficacy of cefcanel daloxate in comparison with cefaclor.
Lionell, C; Magni, L, 1990)		2.05

Pharmacokinetics

ExcerptReferenceRelevance
" Cefcanel renal clearance and fraction excreted in the urine were linearly correlated with renal function and thus, logarithmic increases in plasma area under the concentration versus time curve and plasma elimination half-life were seen with decreasing GFR."( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function.
Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994)		0.59

Bioavailability

ExcerptReferenceRelevance
" The absolute oral bioavailability of cefcanel was approximately 40% after administration of cefcanel daloxate hydrochloride and the extent of urinary excretion of cefcanel, mandelic acid glycine conjugate, and N-mandelyl-2-aminoethanol after an equimolar intravenous administration of cefcanel, were determined in a separate, similar group of volunteers (N = 12, group B)."( Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects.
Arvidsson, A; Edwall, B; Lake-Bakaar, D; Lanbeck-Vallén, K; Yisak, W, )		0.65

Dosage Studied

ExcerptRelevanceReference
" Although steady state kinetics were not performed our findings suggest that a dosage reduction is not necessary even in pre-uraemic patients."( Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function.
Dahl, K; Edwall, B; Slettevold, L; Thurmann-Nielsen, E; Torrång, A; Walstad, R, 1994)		0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (44.44)18.7374
1990's5 (55.56)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
iohexol
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.		1.9810benzenedicarboxamide;
organoiodine compound		environmental contaminant;
radioopaque medium;
xenobiotic
cefazolin
Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.		2.3820beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles		antibacterial drug
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		3.3711penicillin allergen;
penicillin		antibacterial drug
cefaclor anhydrous
Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.		3.7721cephalosporinantibacterial drug;
drug allergen
cephalosporin c
cephalosporin C: RN given refers to parent cpd; structure in Merck, 9th ed, #1937. cephalosporin C : A cephalosporin antibiotic carrying a 3-acetoxymethyl substituent and a 6-oxo-N(6)-L-lysino group at position 7.		5.5392cephalosporinfungal metabolite
cefcanel
cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure		7.3820
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		04.0531
Haemophilus Infections
Infections with bacteria of the genus HAEMOPHILUS.		03.3711
Sinusitis, Maxillary
[description not available]		03.3711
Acute Disease
Disease having a short and relatively severe course.		04.3322
Bacterial Infections
Infections by bacteria, general or unspecified.		04.0531
Maxillary Sinusitis
Inflammation of the NASAL MUCOSA in the MAXILLARY SINUS. In many cases, it is caused by an infection of the bacteria HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; or STAPHYLOCOCCUS AUREUS.		03.3711
Kidney Failure
A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.		01.9810
Renal Insufficiency
Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.		01.9810
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		04.0531
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		01.9710
E coli Infections
[description not available]		01.9710
Infections, Klebsiella
[description not available]		01.9710
Infections, Staphylococcal
[description not available]		01.9710
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		01.9710
Klebsiella Infections
Infections with bacteria of the genus KLEBSIELLA.		01.9710
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		01.9710
Infections, Respiratory
[description not available]		01.9710
Respiratory Tract Infections
Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.		01.9710